File downloaded on 2026-11-18
Source URL: https://medicines.health.europa.eu/veterinary/en/600000085453

Nafpenzal DC Suspensie voor intramammair gebruik

Authorised

- Benzylpenicillin procaine
- Dihydrostreptomycin sulfate
- Nafcillin sodium

Product identification

Medicine name:
Nafpenzal DC Suspensie voor intramammair gebruik

Active substance:
Benzylpenicillin procaine

Dihydrostreptomycin sulfate

Nafcillin sodium

Target species:
Cattle (dry cow)

Route of administration:
Intramammary use

Product details

Active substance and strength:
Benzylpenicillin procaine

300.00 milligram(s) / 1.00 Syringe

Dihydrostreptomycin sulfate
125.00 milligram(s) / 1.00 Syringe

Nafcillin sodium
109.00 milligram(s) / 1.00 Syringe

Pharmaceutical form:
Intramammary suspension

Withdrawal period by route of administration:
Intramammary use:

- **Cattle (dry cow)**
  - Meat and offal. 5 week
  - Milk. no withdrawal period

Treatment to calving interval ≥ 46 days: 48 hours; Treatment to calving interval < 46 days: 46 days after treatment.

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QJ51RC23

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

---

Authorisation status:
Valid

Authorised in:
Belgium

Available in:
Belgium

Package description:
Nafpenzal DC 5 x 4 Intramammary syringes with 3g of Intramammary suspension
Nafpenzal DC 20 Intramammary syringes with 3g of Intramammary suspension
Nafpenzal DC 6 x 20 Intramammary syringes with 3g of Intramammary suspension

Nafpenzal DC 100 Intramammary syringes with 3 g of Intramammary suspension

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Legal basis not covered by Directive 2001/82/EC

Marketing authorisation holder:
Intervet International B.V.

Marketing authorisation date:
1/08/1972

Manufacturing sites for batch release:
Intervet International B.V.

Responsible authority:
Federal Agency For Medicines And Health Products

Authorisation number:
BE-V023572

Date of authorisation status change:
8/12/2023

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.

Package Leaflet

This document does not exist in this language (English). You can find it in another language below.

Labelling

This document does not exist in this language (English). You can find it in another language below.